Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

London pre-open: Stocks set for positive start

(Sharecast News) - London stocks were set to rise at the open on Tuesday following a mostly positive Asian session. The FTSE 100 was called to open 25 points higher at 7,258.

Naeem Aslam, chief market analyst at Ava Trade, said: "As most traders return from the July Fourth holiday, European and US futures are trading higher today. There is also a lot of optimism among traders that the Biden administration could be rolling back some of the tariffs imposed on China during the Trump era to ease inflation.

"Higher inflation has created a significant threat to the US economy, and there are higher chances of the US economy falling into a recession. Investors believe that if President Biden rolls back some of the Trump administration tariffs on China, it will positively impact inflation, meaning we could see inflation numbers falling but not significantly.

"Two important economic events are taking place this week, and traders are highly likely to focus on them. First, we will get the Fed Minutes which will give us more clarity about the Fed's think behind their current hawkish monetary policy. Secondly, and more importantly, the US non-farm payrolls data will be coming out on Friday."

In corporate news, supermarket chain Sainsbury's said first-quarter sales fell 2.4% against last year's elevated Covid-19 driven levels and 8.7% ahead of pre-pandemic levels.

Group sales, excluding fuel for the 16 weeks to June 25 fell 4.5%, but were 5.4% higher than pre-pandemic levels. Sainsbury's maintained guidance for annual underlying profit before tax of between £630m and £690m.

Drugmaker AstraZeneca has agreed to acquire TeneoTwo and its clinical-stage T-cell engager in a deal worth up to $1.26bn as part of an effort to accelerate the development of the potential new medicine for B-cell haematologic malignancies.

AstraZeneca will pay $100.0m for TeneoTwo and its TNB-486 T-cell engager, while additional contingent research and development-related milestone payments of up to $805.0m and further commercial-related milestone payments of up to $360.0m will also be due to TeneoTwo's equity holders.

Share this article

Related Sharecast Articles

London open: Stocks gain as investors mull Rightmove data; inflation eyed
(Sharecast News) - London stocks edged higher early trade on Monday as investors mulled the latest UK house price figures and looked ahead to key inflation data later in the week.
London pre-open: Stocks seen up as investors mull Rightmove data
(Sharecast News) - London stocks were set to rise at the open on Monday as investors mulled the latest UK house price figures.
London close: Stocks recoup some earlier losses
(Sharecast News) - London stocks remained in negative territory by Friday's close, although they managed to recoup some of the losses seen earlier in the session as Wall Street opened with positive momentum.
London midday: FTSE stays down; Auto Trader hit by downgrade
(Sharecast News) - London stocks were still in the red by midday on Friday, having taken their opening cue from a downbeat close on Wall Street.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.